Bioline RX Ltd Sponsored ADR (BLRX) Price & Analysis

Compare

2,542 Followers

BLRX Stock Chart & Stats

$2.87

-$0.02(-10.62%)

At close: Jan 08 4:00 PM EST

$2.87

-$0.02(-10.62%)

Day’s Range― - ―

52-Week Range$2.30 - $7.77

Previous CloseN/A

Volume8.80M

Average Volume (3M)23.61K

Market Cap

$12.41M

Enterprise ValueN/A

Total Cash (Recent Filing)$28.16M

Total Debt (Recent Filing)$12.60M

Price to Earnings (P/E)―

Beta1.29

Next Earnings

Mar 12, 2026

EPS Estimate

-0.39

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding4,351,358

10 Day Avg. Volume24,146

30 Day Avg. Volume23,614

Financial Highlights & Ratios

PEG Ratio0.84

Price to Book (P/B)50.79

Price to Sales (P/S)23.63

P/FCF Ratio-15.56

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$12.00

Price Target Upside318.12% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Regulatory DesignationOrphan Drug Designation from the FDA for GLIX1 provides potential regulatory incentives and market exclusivity that could improve commercial prospects for a glioblastoma therapy.

Strategic PartnershipJoint venture with Hemispherian AS supports development of GLIX1 for glioblastoma and other cancers by combining resources and expertise to advance clinical development.

Therapeutic DifferentiationGLIX1's ability to cross the blood-brain barrier and its synergistic activity with PARP inhibitors may differentiate it from existing therapies and broaden applicability to difficult-to-treat brain cancers.

Bears Say

Bioline RX Ltd Sponsored ADR News

BioLineRx Earnings Call: Strategic Initiatives Amid Revenue Challenges

Bioline RX Ltd Sponsored ADR (($BLRX)) has held its Q3 earnings call. Read on for the main highlights...

2M ago

BLRX

BioLineRx Reports Q3 2025 Results and Strategic Expansion

Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has released its Q3 earnings. Here is a breakdown of...

2M ago

BLRX

BioLineRx Announces Q3 2025 Financial Results and New Joint Venture

An announcement from Bioline RX Ltd Sponsored ADR ( ($BLRX) ) is now available. On November 24, 2025,...

2M ago

BLRX

Morning Movers: Novo Nordisk sinks after Alzheimer’s disease study results

Stock futures are modestly positive, but there remain lingering concerns around growth, tech valuations and incomplete data. Equity...

2M ago

NVO

WRD

Options Volatility and Implied Earnings Moves Today, November 24, 2025

Today, several major companies are expected to report earnings: Agilent (A), Bioline RX Ltd Sponsored ADR (BLRX), Pennantpark...

2M ago

BioLineRx reports Q3 EPS 0c vs 0c last year

Reports Q3 revenue $427k vs $4.121M last year. “The clear highlight of the third quarter was our announcement...

2M ago

BLRX

Options Volatility and Implied Earnings Moves This Week, November 24 – November 26, 2025

This week, several major companies will be reporting earnings. Among them are Alibaba (BABA), Nio (NIO), Zoom Video...

2M ago

BLRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Bioline RX Ltd Sponsored ADR (BLRX) is scheduled to report 3rd quarter earnings on 11/24/2025, before the market...

2M ago

BLRX

BioLineRx Secures USPTO Patent Allowance for Cancer Treatment with GLIX1

Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has provided an update. On November 17, 2025, BioLineRx Ltd....

2M ago

BLRX

BioLineRx and Hemispherian Launch Joint Venture to Develop GLIX1 for Glioblastoma

Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has issued an update. On September 29, 2025, BioLineRx Ltd....

4M ago

BLRX

BioLineRx, Hemispherian AS establish joint venture to develop GLIX1

BioLineRx (BLRX) and Hemispherian AS, a Norwegian biotech company focused on small molecule cancer therapeutics, announced the establishment...

4M ago

BLRX

BioLineRx ADR Earnings Call: Optimism Amid Challenges

Bioline RX Ltd Sponsored ADR (($BLRX)) has held its Q2 earnings call. Read on for the main highlights...

5M ago

BLRX

BioLineRx: Strategic Pipeline Expansion and Strong Financial Health Justify Buy Rating

JonesTrading analyst Justin Walsh has reiterated their bullish stance on BLRX stock, giving a Buy rating yesterday. Justin...

5M ago

BLRX

BioLineRx reports Q2 EPS 0c vs. 0c last year

Reports Q2 revenue $300K, consensus $661.33K. As of June 30, 2025, the company had cash, cash equivalents, and...

5M ago

BLRX

BLRX FAQ

What was Bioline RX Ltd Sponsored ADR’s price range in the past 12 months?

Bioline RX Ltd Sponsored ADR lowest stock price was $2.30 and its highest was $7.77 in the past 12 months.

What is Bioline RX Ltd Sponsored ADR’s market cap?

Bioline RX Ltd Sponsored ADR’s market cap is $12.41M.

When is Bioline RX Ltd Sponsored ADR’s upcoming earnings report date?

Bioline RX Ltd Sponsored ADR’s upcoming earnings report date is Mar 12, 2026 which is in 55 days.

How were Bioline RX Ltd Sponsored ADR’s earnings last quarter?

Bioline RX Ltd Sponsored ADR released its earnings results on Nov 24, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.67 by $0.67.

Is Bioline RX Ltd Sponsored ADR overvalued?

According to Wall Street analysts Bioline RX Ltd Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bioline RX Ltd Sponsored ADR pay dividends?

Bioline RX Ltd Sponsored ADR does not currently pay dividends.

What is Bioline RX Ltd Sponsored ADR’s EPS estimate?

Bioline RX Ltd Sponsored ADR’s EPS estimate is -0.39.

How many shares outstanding does Bioline RX Ltd Sponsored ADR have?

Bioline RX Ltd Sponsored ADR has 4,351,358 shares outstanding.

What happened to Bioline RX Ltd Sponsored ADR’s price movement after its last earnings report?

Bioline RX Ltd Sponsored ADR reported an EPS of $0 in its last earnings report, beating expectations of -$0.67. Following the earnings report the stock price went up 7.692%.

Which hedge fund is a major shareholder of Bioline RX Ltd Sponsored ADR?

Currently, no hedge funds are holding shares in BLRX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bioline RX Ltd Sponsored ADR

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Bioline RX Ltd Sponsored ADR (BLRX) Earnings & Revenues

Historic Earnings Reports

BLRX Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mix of positive developments in R&D ventures and strong financial management, offset by minimal revenue growth and reduced operational expenses. The company's strategic focus on innovative treatments and a solid cash position are promising, but current revenue generation and market penetration remain challenges.View all BLRX earnings summaries

BLRX Stock 12 Month Forecast

Average Price Target

$12.00

▲(318.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","7":"$7","10":"$10","13":"$13"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4,7,10,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.77,3.48,4.19,4.9,5.61,6.32,7.030000000000001,7.74,8.450000000000001,9.16,9.870000000000001,10.58,11.290000000000001,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.77,3.48,4.19,4.9,5.61,6.32,7.030000000000001,7.74,8.450000000000001,9.16,9.870000000000001,10.58,11.290000000000001,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.77,3.48,4.19,4.9,5.61,6.32,7.030000000000001,7.74,8.450000000000001,9.16,9.870000000000001,10.58,11.290000000000001,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.53,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >